Overview

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Status:
Completed

Trial end date:
2020-11-06

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard dose PPIs.

Phase:

Phase 3

Details

Lead Sponsor:

Ironwood Pharmaceuticals, Inc.

Treatments:

Proton Pump Inhibitors